• Home
  • News
  • Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking

Captor Therapeutics ®


Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking


Wroclaw, Poland, 23 March, 2022 - Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, was awarded the title of Stock Exchange Company of the Year in the Innovation category.

Wrocław-based biopharmaceutical company was awarded first place in the category "Products and Services Innovation” in the 23rd edition of the ranking organized by the main business daily newspaper Puls Biznesu. The results of the competition confirm the achievements of the Company and place it among the leading entities listed on the Warsaw Stock Exchange. This is a particularly valuable recognition, as Captor is a stock exchange debutant - the Company has only been listed on the WSE since April 2021.

- This award in the Stock Exchange Company of the Year competition granted by the key figures of the Polish capital market is a great honour and shows that the market understands and appreciates the development of innovative projects in Captor`s pipeline of new therapies. Our technology is not only innovative, but may bring breakthroughs in treating severe diseases through addressing molecular targets which are so far considered untreatable. We would like to thank the jury for selecting our company and all the investors for their trust and support – this recognition is a great additional motivator for the whole Captor team and confirms our focus on innovation to further develop our projects - Thomas Shepherd, CEO of Captor Therapeutics, said.

Recently, Captor Therapeutics has reported several positive results from its ongoing research and development work. These include information on the effective degradation of MCL- 1 protein by the drug candidate CT-03 and promising results of preclinical proof-of-concept in-vivo studies that demonstrate the very significant anti-tumour activity of two lead compounds being developed under project CT-01. Captor Therapeutics has also opened a state-of-the-art Proteomics Laboratory for advanced analyses based on mass spectrometry.

The Stock Exchange Company of the Year ranking is one of the oldest and most appreciated listings on the Polish capital market. Every year, the best listed companies are chosen by 100 professionals – market analysts, investment and management advisors and institutional investors. Experts measure companies in five categories: the management board competencies, success, products and services innovation, investor relations, and development perspectives.

About Captor Therapeutics

Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs. TPD is a revolutionary approach to developing new drugs that can address novel molecular targets which are deemed “undruggable” with classical drug development approaches, as well as providing additional treatment options for diseases where existing drugs fail to provide an optimal medical benefit. Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.  

More information on Captor Therapeutics is available at: http://www.captortherapeutics.com

LinkedIn: @CaptorTherapeutics

Twitter: @CaptorTherapeu1

For further information, please contact:

Polish Media and Investor relations:

Point of View

Bartosz Sawulski

+48 694 400 787


International Investor Relations:

LifeSci Advisors

Guillaume van Renterghem

+41 (0)76 735 01 31